191 related articles for article (PubMed ID: 23820407)
1. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease.
Furuta GT; Atkins D; Capocelli KE; de Zoeten EF; Fleischer D; Menard-Katcher C
J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25. PubMed ID: 23820407
[No Abstract] [Full Text] [Related]
2. Authors' response.
Turner D; Friesen C
J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25-6. PubMed ID: 23820406
[No Abstract] [Full Text] [Related]
3. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease.
Turner D; Wolters VM; Russell RK; Shakhnovich V; Muise AM; Ledder O; Ngan B; Friesen C
J Pediatr Gastroenterol Nutr; 2013 May; 56(5):492-7. PubMed ID: 23221994
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
Kane S
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):293-4. PubMed ID: 23247325
[No Abstract] [Full Text] [Related]
5. [Patient information. Biological agents in inflammatory bowel disease].
Van Domselaar M
Rev Esp Enferm Dig; 2008 Dec; 100(12):798. PubMed ID: 19238770
[No Abstract] [Full Text] [Related]
6. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
Sipponen T; Kolho KL
Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
[TBL] [Abstract][Full Text] [Related]
7. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
8. Head-to-head trials in inflammatory bowel disease.
Radford-Smith G
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():18-19. PubMed ID: 33817853
[No Abstract] [Full Text] [Related]
9. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
Salgueiro P; Lago P; Pedroto I
J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
[No Abstract] [Full Text] [Related]
10. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
11. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
14. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
Licinio R; Losurdo G; Ierardi E; Di Leo A; Principi M
Aliment Pharmacol Ther; 2015 Jun; 41(12):1302. PubMed ID: 25968153
[No Abstract] [Full Text] [Related]
15. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.
Macaluso FS; Criscuoli V; Orlando E; Rizzuto G; Renna S; Cottone M; Orlando A
Aliment Pharmacol Ther; 2016 May; 43(9):1019-20. PubMed ID: 27040168
[No Abstract] [Full Text] [Related]
16. Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.
Miranda-Bautista J; de Gracia-Fernández C; López-Ibáñez M; Barrientos M; Gallo-Moltó A; González-Arias M; González-Gil C; Díaz-Redondo A; Marín-Jiménez I; Menchén L
Dig Dis Sci; 2015 Jul; 60(7):2130-5. PubMed ID: 25680875
[TBL] [Abstract][Full Text] [Related]
17. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
Gisbert JP; Chaparro M
Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
[No Abstract] [Full Text] [Related]
18. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
19. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
Gisbert JP; Chaparro M
Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
[No Abstract] [Full Text] [Related]
20. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
